Symbols / QNCX
QNCX Chart
About
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 7.75M |
| Enterprise Value | -544.14K | Income | -56.98M | Sales | — |
| Book/sh | 0.02 | Cash/sh | 0.47 | Dividend Yield | — |
| Payout | 0.00% | Employees | 36 | IPO | — |
| P/E | — | Forward P/E | -0.12 | PEG | — |
| P/S | — | P/B | 7.33 | P/C | — |
| EV/EBITDA | 0.01 | EV/Sales | — | Quick Ratio | 1.05 |
| Current Ratio | 1.12 | Debt/Eq | 1699.06 | LT Debt/Eq | — |
| EPS (ttm) | -1.20 | EPS next Y | -1.17 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-23 | ROA | -22.10% |
| ROE | -247.78% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 55.68M |
| Shs Float | 49.76M | Short Float | 3.76% | Short Ratio | 0.51 |
| Short Interest | — | 52W High | 4.55 | 52W Low | 0.12 |
| Beta | 1.24 | Avg Volume | 53.44M | Volume | 20.41M |
| Target Price | $0.00 | Recom | None | Prev Close | $0.14 |
| Price | $0.14 | Change | 1.61% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.14
Latest analyst target
3. DCF / Fair value
$-5.81
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.14
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-30 | down | Citizens | Market Outperform → Market Perform | — |
| 2026-01-30 | down | D. Boral Capital | Buy → Hold | — |
| 2026-01-29 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-12-15 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-11-13 | main | D. Boral Capital | Buy → Buy | $4 |
| 2025-09-26 | main | D. Boral Capital | Buy → Buy | $4 |
| 2025-08-15 | main | D. Boral Capital | Buy → Buy | $4 |
| 2025-08-12 | main | JMP Securities | Market Outperform → Market Outperform | $8 |
| 2025-08-05 | init | JMP Securities | — → Market Outperform | $9 |
| 2025-07-17 | main | D. Boral Capital | Buy → Buy | $4 |
| 2025-06-13 | main | D. Boral Capital | Buy → Buy | $4 |
| 2025-06-04 | main | D. Boral Capital | Buy → Buy | $4 |
| 2025-03-25 | main | D. Boral Capital | Buy → Buy | $4 |
| 2025-03-24 | init | Oppenheimer | — → Outperform | $10 |
| 2025-02-05 | main | D. Boral Capital | Buy → Buy | $12 |
| 2025-01-02 | main | D. Boral Capital | Buy → Buy | $12 |
| 2024-12-18 | init | Brookline Capital | — → Buy | $9 |
| 2024-11-14 | main | D. Boral Capital | Buy → Buy | $12 |
| 2024-11-12 | main | D. Boral Capital | Buy → Buy | $12 |
| 2024-11-07 | init | Maxim Group | — → Buy | $6 |
- Quince Therapeutics explores mergers, deals with LifeSci - Stock Titan Mon, 09 Feb 2026 08
- What Sparked Quince Therapeutics (QNCX) Stock To Rise 53% After Hours - Sahm Wed, 18 Feb 2026 15
- Why Is QNCX Stock Up 60% Pre-Market After A Near-Total Wipeout? - Stocktwits ue, 10 Feb 2026 08
- Quince Therapeutics stock plummets after revealing strategic alternatives - Investing.com hu, 12 Feb 2026 08
- $QNCX stock is down 12% today. Here's what we see in our data. - Quiver Quantitative ue, 17 Feb 2026 19
- Why Is Quince Therapeutics Stock (QNCX) Up Today? - TipRanks ue, 10 Feb 2026 08
- Quince Therapeutics (QNCX) stock slides before the bell after LifeSci Capital deal review move - TechStock² ue, 10 Feb 2026 08
- Quince Therapeutics Exploring Strategic Alternatives; Stock Soars - Nasdaq ue, 10 Feb 2026 08
- QNCX (Quince Therapeutics) NASDAQ intraday up 182.82% to $0.39: watch strategic-review momentum - Meyka ue, 10 Feb 2026 08
- Quince Therapeutics’ stock crashes on Phase III ataxia-telangiectasia failure - Yahoo Finance Mon, 02 Feb 2026 08
- Quince Therapeutics Stock Rockets 59% With 7-Day Winning Streak - Trefis Wed, 26 Nov 2025 08
- Rare disease hope stalls as eDSP trial fails and Quince halts development - Stock Titan hu, 29 Jan 2026 08
- Quince Therapeutics (QNCX) stock price jumps in premarket as strategic review keeps deal talk alive - TechStock² Wed, 11 Feb 2026 08
- Why Did QNCX Stock Plummet Over 90% Today? - Stocktwits hu, 29 Jan 2026 23
- Quince Therapeutics stock tumbles after failed Phase 3 trial results - Investing.com hu, 29 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 50000 | 173500 | — | Sale at price 3.47 per share. | LUCA BENATTI | Director | — | 2025-12-26 00:00:00 | D |
| 1 | 739885 | — | — | Stock Gift at price 0.00 per share. | THYE DIRK | Chief Executive Officer | — | 2025-12-10 00:00:00 | D |
| 2 | 27551 | 25012 | — | Conversion of Exercise of derivative security at price 0.55 - 0.94 per share. | HANNAH BRENDAN | Chief Operating Officer | — | 2025-12-05 00:00:00 | D |
| 3 | 7548 | 9058 | — | Stock Award(Grant) at price 1.20 per share. | RYAN CHARLES S | President | — | 2025-06-18 00:00:00 | D |
| 4 | 150944 | 181133 | — | Stock Award(Grant) at price 1.20 per share. | THYE DIRK | Chief Executive Officer | — | 2025-06-18 00:00:00 | D |
| 5 | 37736 | 45283 | — | Stock Award(Grant) at price 1.20 per share. | HANNAH BRENDAN | Chief Operating Officer | — | 2025-06-18 00:00:00 | D |
| 6 | 154500 | 107375 | — | Purchase at price 0.69 - 0.70 per share. | THYE DIRK | Chief Executive Officer | — | 2024-08-30 00:00:00 | D |
| 7 | 38924 | 24166 | — | Purchase at price 0.58 - 0.63 per share. | HANNAH BRENDAN | Chief Operating Officer | — | 2024-08-21 00:00:00 | D |
| 8 | 48387 | 31452 | — | Purchase at price 0.65 per share. | RYAN CHARLES S | President | — | 2024-08-20 00:00:00 | D |
| 9 | 56061 | 30834 | — | Conversion of Exercise of derivative security at price 0.55 per share. | HANNAH BRENDAN | Chief Operating Officer | — | 2024-06-04 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -4.43M | -46.36K | -4.54K | 0.00 |
| TaxRateForCalcs | 0.21 | 0.01 | 0.01 | 0.00 |
| NormalizedEBITDA | -14.87M | -19.34M | -50.16M | -89.97M |
| TotalUnusualItems | -21.11M | -7.48M | -825.00K | 0.00 |
| TotalUnusualItemsExcludingGoodwill | -21.11M | -7.48M | -825.00K | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -56.83M | -31.39M | -51.66M | -89.94M |
| ReconciledDepreciation | 186.00K | 322.00K | 204.00K | 344.00K |
| EBITDA | -35.98M | -26.82M | -50.99M | -89.97M |
| EBIT | -36.17M | -27.14M | -51.19M | -90.32M |
| NetInterestIncome | 2.93M | 3.48M | 1.07M | 620.00K |
| InterestIncome | 2.93M | 3.48M | 1.07M | 620.00K |
| NormalizedIncome | -40.15M | -23.95M | -50.84M | -89.94M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -56.83M | -31.39M | -51.66M | -89.94M |
| TotalExpenses | 36.17M | 27.14M | 51.19M | 90.32M |
| TotalOperatingIncomeAsReported | -57.28M | -34.62M | -52.02M | -90.32M |
| DilutedAverageShares | 43.26M | 37.24M | 33.50M | 29.72M |
| BasicAverageShares | 43.26M | 37.24M | 33.50M | 29.72M |
| DilutedEPS | -1.31 | -0.84 | -1.54 | -3.03 |
| BasicEPS | -1.31 | -0.84 | -1.54 | -3.03 |
| DilutedNIAvailtoComStockholders | -56.83M | -31.39M | -51.66M | -89.94M |
| NetIncomeCommonStockholders | -56.83M | -31.39M | -51.66M | -89.94M |
| NetIncome | -56.83M | -31.39M | -51.66M | -89.94M |
| NetIncomeIncludingNoncontrollingInterests | -56.83M | -31.39M | -51.66M | -89.94M |
| NetIncomeContinuousOperations | -56.83M | -31.39M | -51.66M | -89.94M |
| TaxProvision | 87.00K | -197.00K | -284.00K | 0.00 |
| PretaxIncome | -56.74M | -31.58M | -51.94M | -89.94M |
| OtherIncomeExpense | -23.50M | -7.92M | -1.82M | -247.00K |
| OtherNonOperatingIncomeExpenses | -2.38M | -440.00K | -997.00K | -247.00K |
| SpecialIncomeCharges | -21.11M | -7.48M | -825.00K | 0.00 |
| ImpairmentOfCapitalAssets | 17.13M | 5.90M | 825.00K | 0.00 |
| RestructuringAndMergernAcquisition | 3.98M | 1.58M | 0.00 | |
| NetNonOperatingInterestIncomeExpense | 2.93M | 3.48M | 1.07M | 620.00K |
| InterestIncomeNonOperating | 2.93M | 3.48M | 1.07M | 620.00K |
| OperatingIncome | -36.17M | -27.14M | -51.19M | -90.32M |
| OperatingExpense | 36.17M | 27.14M | 51.19M | 90.32M |
| ResearchAndDevelopment | 18.59M | 9.45M | 25.18M | 60.80M |
| SellingGeneralAndAdministration | 17.58M | 17.70M | 26.01M | 29.52M |
| GeneralAndAdministrativeExpense | 17.58M | 17.70M | 26.01M | 29.52M |
| OtherGandA | 17.58M | 17.70M | 26.01M | 29.52M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 44.00M | 42.97M | 36.14M | 30.07M |
| ShareIssued | 44.00M | 42.97M | 36.14M | 30.07M |
| NetDebt | 8.11M | |||
| TotalDebt | 14.81M | 13.81M | 453.00K | 1.16M |
| TangibleBookValue | -29.90M | 3.79M | 94.69M | 118.59M |
| InvestedCapital | 44.47M | 98.51M | 100.59M | 118.59M |
| WorkingCapital | 36.76M | 67.87M | 90.68M | 97.45M |
| NetTangibleAssets | -29.90M | 3.79M | 94.69M | 118.59M |
| CapitalLeaseObligations | 490.00K | 385.00K | 453.00K | 1.16M |
| CommonStockEquity | 30.15M | 85.08M | 100.59M | 118.59M |
| TotalCapitalization | 44.47M | 98.51M | 100.59M | 118.59M |
| TotalEquityGrossMinorityInterest | 30.15M | 85.08M | 100.59M | 118.59M |
| StockholdersEquity | 30.15M | 85.08M | 100.59M | 118.59M |
| GainsLossesNotAffectingRetainedEarnings | -35.00K | 3.05M | -289.00K | -79.00K |
| OtherEquityAdjustments | -35.00K | 3.05M | -289.00K | -79.00K |
| RetainedEarnings | -376.47M | -319.64M | -288.26M | -236.60M |
| AdditionalPaidInCapital | 406.61M | 401.64M | 389.11M | 355.23M |
| CapitalStock | 44.00K | 43.00K | 36.00K | 30.00K |
| CommonStock | 44.00K | 43.00K | 36.00K | 30.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 84.33M | 82.82M | 3.32M | 14.64M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 77.05M | 73.24M | 248.00K | 420.00K |
| OtherNonCurrentLiabilities | 57.38M | 54.19M | ||
| NonCurrentAccruedExpenses | 53.60M | 0.00 | ||
| NonCurrentDeferredLiabilities | 4.96M | 5.30M | 248.00K | 0.00 |
| NonCurrentDeferredTaxesLiabilities | 4.96M | 5.30M | 248.00K | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 14.71M | 13.75M | 0.00 | 420.00K |
| LongTermCapitalLeaseObligation | 394.00K | 321.00K | 0.00 | 420.00K |
| LongTermDebt | 14.32M | 13.43M | ||
| CurrentLiabilities | 7.28M | 9.57M | 3.07M | 14.22M |
| OtherCurrentLiabilities | 308.00K | 4.36M | 185.00K | 180.00K |
| CurrentDebtAndCapitalLeaseObligation | 96.00K | 64.00K | 453.00K | 741.00K |
| CurrentCapitalLeaseObligation | 96.00K | 64.00K | 453.00K | 741.00K |
| PayablesAndAccruedExpenses | 6.87M | 5.15M | 2.43M | 13.30M |
| CurrentAccruedExpenses | 3.97M | 3.12M | 1.86M | 8.39M |
| Payables | 2.90M | 2.03M | 570.00K | 4.91M |
| AccountsPayable | 2.90M | 2.03M | 570.00K | 4.91M |
| TotalAssets | 114.48M | 167.90M | 103.91M | 133.23M |
| TotalNonCurrentAssets | 70.44M | 90.46M | 10.16M | 21.55M |
| OtherNonCurrentAssets | 10.00K | 194.00K | ||
| NonCurrentAccountsReceivable | 9.51M | 8.46M | ||
| InvestmentsAndAdvances | 78.00K | 78.00K | 3.58M | 19.93M |
| InvestmentinFinancialAssets | 78.00K | 78.00K | 3.58M | 19.93M |
| AvailableForSaleSecurities | 78.00K | 78.00K | 3.58M | 19.93M |
| GoodwillAndOtherIntangibleAssets | 60.05M | 81.30M | 5.90M | 0.00 |
| OtherIntangibleAssets | 60.05M | 63.67M | 5.90M | |
| Goodwill | 0.00 | 17.62M | 0.00 | |
| NetPPE | 813.00K | 619.00K | 684.00K | 1.43M |
| AccumulatedDepreciation | -639.00K | -507.00K | -185.00K | -959.00K |
| GrossPPE | 1.45M | 1.13M | 869.00K | 2.39M |
| Leases | 34.00K | 36.00K | 21.00K | 58.00K |
| OtherProperties | 1.13M | 871.00K | 830.00K | 2.25M |
| MachineryFurnitureEquipment | 285.00K | 219.00K | 18.00K | 79.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 44.04M | 77.44M | 93.75M | 111.67M |
| OtherCurrentAssets | 84.00K | 81.00K | 276.00K | 367.00K |
| PrepaidAssets | 2.29M | 1.31M | 2.29M | 3.38M |
| Receivables | 882.00K | 993.00K | 1.00M | 1.13M |
| TaxesReceivable | 882.00K | 993.00K | 1.00M | 1.13M |
| CashCashEquivalentsAndShortTermInvestments | 40.78M | 75.06M | 90.18M | 106.80M |
| OtherShortTermInvestments | 34.57M | 54.31M | 45.60M | 37.08M |
| CashAndCashEquivalents | 6.21M | 20.75M | 44.58M | 69.72M |
| CashEquivalents | 3.70M | 19.23M | 40.59M | 29.45M |
| CashFinancial | 2.51M | 1.52M | 3.99M | 40.27M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -32.16M | -18.45M | -44.17M | -63.11M |
| RepaymentOfDebt | 0.00 | -6.00K | -49.00K | 0.00 |
| IssuanceOfCapitalStock | 0.00 | 608.00K | 0.00 | |
| CapitalExpenditure | -257.00K | -160.00K | -133.00K | -180.00K |
| EndCashPosition | 6.21M | 20.75M | 44.58M | 69.72M |
| BeginningCashPosition | 20.75M | 44.58M | 69.72M | 66.84M |
| EffectOfExchangeRateChanges | 231.00K | 80.00K | 184.00K | 55.00K |
| ChangesInCash | -14.77M | -23.91M | -25.33M | 2.83M |
| FinancingCashFlow | -4.78M | 143.00K | 707.00K | 6.81M |
| CashFlowFromContinuingFinancingActivities | -4.78M | 143.00K | 707.00K | 6.81M |
| NetOtherFinancingCharges | -5.00M | |||
| ProceedsFromStockOptionExercised | 225.00K | 149.00K | 148.00K | 6.81M |
| NetCommonStockIssuance | 0.00 | 608.00K | 0.00 | |
| CommonStockIssuance | 0.00 | 608.00K | 0.00 | |
| NetIssuancePaymentsOfDebt | 0.00 | -6.00K | -49.00K | 0.00 |
| NetLongTermDebtIssuance | 0.00 | -6.00K | -49.00K | 0.00 |
| LongTermDebtPayments | 0.00 | -6.00K | -49.00K | 0.00 |
| InvestingCashFlow | 21.91M | -5.76M | 18.00M | 58.95M |
| CashFlowFromContinuingInvestingActivities | 21.91M | -5.76M | 18.00M | 58.95M |
| NetOtherInvestingChanges | -910.00K | 70.00K | ||
| NetInvestmentPurchaseAndSale | 22.16M | -2.57M | 7.47M | 59.13M |
| SaleOfInvestment | 111.73M | 111.21M | 82.49M | 97.92M |
| PurchaseOfInvestment | -89.56M | -113.78M | -75.02M | -38.79M |
| NetBusinessPurchaseAndSale | 0.00 | -2.12M | 10.59M | 0.00 |
| SaleOfBusiness | 0.00 | 10.59M | 0.00 | |
| PurchaseOfBusiness | 0.00 | -2.12M | 0.00 | |
| NetPPEPurchaseAndSale | -257.00K | -160.00K | -133.00K | -180.00K |
| PurchaseOfPPE | -257.00K | -160.00K | -133.00K | -180.00K |
| OperatingCashFlow | -31.90M | -18.29M | -44.04M | -62.93M |
| CashFlowFromContinuingOperatingActivities | -31.90M | -18.29M | -44.04M | -62.93M |
| ChangeInWorkingCapital | -484.00K | 1.98M | -9.83M | -4.26M |
| ChangeInOtherWorkingCapital | -135.00K | |||
| ChangeInOtherCurrentAssets | -741.00K | -9.00K | 194.00K | -155.00K |
| ChangeInPayablesAndAccruedExpense | 2.10M | -2.26M | -12.60M | -3.28M |
| ChangeInAccruedExpense | 1.18M | -1.97M | -6.66M | -4.63M |
| ChangeInPayable | 927.00K | -288.00K | -5.94M | 1.36M |
| ChangeInAccountPayable | 927.00K | -288.00K | -5.94M | 1.36M |
| ChangeInPrepaidAssets | -1.71M | 4.25M | 2.58M | -829.00K |
| OtherNonCashItems | 5.69M | 1.67M | -313.00K | 199.00K |
| StockBasedCompensation | 4.75M | 5.22M | 16.62M | 29.85M |
| AssetImpairmentCharge | 17.13M | 5.97M | 961.00K | 0.00 |
| AmortizationOfSecurities | -2.35M | -2.02M | -113.00K | 878.00K |
| DepreciationAmortizationDepletion | 186.00K | 322.00K | 204.00K | 344.00K |
| DepreciationAndAmortization | 186.00K | 322.00K | 204.00K | 344.00K |
| OperatingGainsLosses | -41.00K | 94.00K | ||
| GainLossOnSaleOfPPE | 0.00 | -41.00K | 94.00K | 0.00 |
| NetIncomeFromContinuingOperations | -56.83M | -31.39M | -51.66M | -89.94M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for QNCX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|